Urolithin A (Mitopure)

Urolithin A is a postbiotic compound produced by gut bacteria from ellagitannins found in pomegranates and berries. It activates mitophagy, the cellular process that removes damaged mitochondria and promotes the generation of new, healthy mitochondria.

Origin & History

Urolithin A is a metabolite produced by gut bacteria from ellagitannins, compounds found in foods like pomegranates and berries. Mitopure is a patented, pure form of Urolithin A, manufactured through a controlled fermentation process to ensure consistency and potency.

Historical & Cultural Context

Urolithin A is a metabolite derived from ellagitannins found in pomegranates and other fruits, traditionally consumed for their health benefits.

Health Benefits

- Enhances mitochondrial function by increasing ATP production, boosting cellular energy levels. - Supports muscle health by improving endurance and strength, as shown in studies with a 15% increase in muscle function. - Promotes longevity by activating pathways linked to lifespan extension, such as AMPK and sirtuins. - Reduces inflammation by decreasing pro-inflammatory cytokines, supporting overall health. - Improves cognitive function by enhancing mitochondrial efficiency in brain cells, leading to better memory and focus. - Supports cardiovascular health by improving endothelial function, which can reduce the risk of heart disease. - Aids in weight management by increasing fat oxidation, helping to maintain a healthy weight.

How It Works

Urolithin A activates mitophagy by upregulating PINK1/Parkin signaling pathways and increasing expression of PGC-1α, the master regulator of mitochondrial biogenesis. It enhances AMPK phosphorylation and activates SIRT1, promoting cellular energy metabolism and longevity pathways. The compound also modulates NF-κB signaling to reduce inflammatory responses in muscle tissue.

Scientific Research

Urolithin A has been studied for its ability to induce mitophagy, with several clinical trials showing improvements in muscle function and mitochondrial health.

Clinical Summary

A randomized controlled trial with 66 elderly adults showed 500mg daily Urolithin A improved muscle endurance by 15% and increased ATP production in skeletal muscle after 4 months. Another study with 32 participants demonstrated enhanced mitochondrial gene expression and reduced inflammatory markers after 8 weeks of supplementation. However, most human studies are small-scale and short-term, with larger long-term trials needed to confirm sustained benefits. Animal studies show more robust evidence for longevity and muscle preservation effects.

Nutritional Profile

Urolithin A (Mitopure) is not a traditional food but a postbiotic metabolite naturally produced by gut microbiota (primarily Gordonibacter and Ellagibacter species) through fermentation of ellagitannins and ellagic acid found in pomegranates, walnuts, raspberries, and strawberries. As a bioactive compound, it has negligible macronutrient content (no significant protein, fat, carbohydrate, or fiber contribution). Key bioactive compound: Urolithin A (6H-dibenzo[b,d]pyran-6-one derivative), typically standardized at 500 mg per dose in commercial Mitopure formulations. Bioavailability notes: Only approximately 40% of the population possesses the gut microbiome capable of endogenously converting ellagitannins to Urolithin A, making direct supplementation significant. Oral bioavailability is moderate; Urolithin A undergoes phase II metabolism forming glucuronide and sulfate conjugates in the liver and intestinal wall. Peak plasma concentration (Cmax) is reached approximately 6–8 hours post-ingestion. Plasma half-life is approximately 17–25 hours, supporting once-daily dosing. The compound is lipophilic (molecular weight: 228.2 g/mol), and absorption may be enhanced when taken with a fat-containing meal. No vitamins or minerals are present in meaningful amounts. The primary mechanism of action involves selective mitophagy induction via PINK1/Parkin pathway activation, clearing dysfunctional mitochondria and stimulating biogenesis. Clinical doses studied range from 250 mg to 1000 mg/day, with 500 mg being the most commonly researched effective dose. Mitopure formulations may include additional carrier ingredients such as medium-chain triglycerides (MCTs) or pomegranate fruit extract providing trace ellagic acid (~50–100 mg) as a complementary polyphenol. Urolithin A also activates AMPK and sirtuin (SIRT1/SIRT3) signaling pathways, upregulates NAD+ metabolism, and has demonstrated reduction in circulating C-reactive protein (CRP) and pro-inflammatory cytokines (IL-6, TNF-α) in clinical trials.

Preparation & Dosage

Dosage typically ranges from 250 mg to 500 mg per day. Consult a healthcare provider before use.

Synergy & Pairings

Pomegranate Extract, CoQ10, Resveratrol

Safety & Interactions

Urolithin A appears well-tolerated with no serious adverse effects reported in clinical trials at doses up to 1000mg daily. Mild gastrointestinal symptoms including nausea and stomach discomfort occur in approximately 5-10% of users. No significant drug interactions have been identified, though it may theoretically enhance effects of diabetes medications due to improved glucose metabolism. Safety during pregnancy and breastfeeding has not been established, so use should be avoided in these populations.